|
Syncona Ltd on Monday said investee Freeline Therapeutics Holdings PLC has presented partial safety and efficacy data from a phase I/II dose confirmation trial for FLT180a, a gene therapy for haemophilia B.
After being treated with Freeline's gene therapy candidate FLT180a, patients were able to stop FIX prophylactic replacement therapy, which is used to stop bleeding and involves frequent intravenous infusions. There were no serious side effects.
‘Syncona is supportive of Freeline's decision to review the appropriate path forward for the programme,’ said Chris Hollowood, chief investment officer of Syncona Investment Management Ltd and chair of Freeline.
Syncona shares were 1.2% lower at 195.56 pence each in London on Monday morning.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
